Why a trial?, page-28

In the big scheme of things, the company is bringing in 11 million a year in royalties and climbing, market value under 300 million.

Back pain phase 3 product that reduces back pain
CHF phase 3 product that reduces 3 point mace, overall survival, non fatal heart attack and strokes
GvHD phase 3 product that reduces mortality
Crohns phase 1/2 product that had 4 patients all in remission

Yes - usually FDA need 1 more trial. So thats' what MSB should do.

Forget the share price, the cells work. Get the cash, partner up and get going !

With 70 million in the bank, and plenty of funding options, not as grim as people think